Table 1 Covid-19 vaccines submitted for WHO emergency use listing
Name | Company | Date of WHO Emergency Use Listing | Platform |
|---|---|---|---|
Comirnaty / Tozinameran / BNT162b2 | Pfizer/BioNtech | 31 December 2020 | Nucleoside modified mRNA |
Vaxzevria / Covishield / ChAdOx1 / AZD1222 | AstraZeneca / Oxford / Serum Institute of India | 16 February 2021 | Recombinant ChAdOx1 adenoviral vector encoding the SARS-CoV-2 Spike protein antigen |
Ad26.COV 2.S | Janssen-Cilag International | 12 March 2021 | Recombinant, replication incompetent adenovirus type 26 vector encoding the SARS-CoV-2 Spike protein |
Spikevax / mRNA-1273 | Moderna Biotech | 30 April 2021 | mRNA-based vaccine encapsulated in lipid nanoparticle |
Sinopharm BIBP COVID-19 vaccine | Sinopharm / Beijing Institute of Biological Products | 7 May 2021 | Inactivated SARS-CoV-2 produced in Vero cells |
CoronaVac / PiCoVacc | Sinovac Life Sciences | 1 June 2021 | Inactivated SARS-CoV-2 produced in Vero cells |
Sputnik V / Gam-COVID-Vac | Gamaleya Research Institute of Epidemiology and Microbiology | pending | Human Adenovirus Vector-based Covid-19 vaccine |
Covaxin / BBV152 | Bharat Biotech | pending | Whole-Virion Inactivated Vero Cell |
Convidecia / AD5-nCOV | CanSino Biologics | pending | Recombinant adenovirus type 5 vector vaccine |
Covovax / NVX-CoV2373 | Novavax | pending | Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant |
Vidprevtyn / VAT00002 / VAT00008 | Sanofi Pasteur / GSK | pending | Recombinant baculovirus vector encoding the SARS-CoV-2 Spike protein, adjuvanted |
SCB-2019 | Clover Biopharmaceuticals | pending | Recombinant SARS-CoV-2 Spike-Trimer fusion protein |
CureVac | CureVac / Coalition for Epidemic Preparedness Innovations | pending | mRNA-based vaccine encapsulated in lipid nanoparticle |